Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease.

Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG.

Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. Epub 2018 Feb 26. Review.

2.

Current and Emerging Multianalyte Assays with Algorithmic Analyses-Are Laboratories Ready for Clinical Adoption?

Colón-Franco JM, Bossuyt PMM, Algeciras-Schimnich A, Bird C, Engstrom-Melnyk J, Fleisher M, Kattan M, Lambert-Messerlian G.

Clin Chem. 2018 Jan 17. pii: clinchem.2017.275677. doi: 10.1373/clinchem.2017.275677. [Epub ahead of print] No abstract available.

PMID:
29343536
3.

Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.

Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI.

J Clin Oncol. 2018 Feb 20;36(6):572-580. doi: 10.1200/JCO.2017.75.2998. Epub 2017 Dec 22.

4.

How well can we quantify dust deposition to the ocean?

Anderson RF, Cheng H, Edwards RL, Fleisher MQ, Hayes CT, Huang KF, Kadko D, Lam PJ, Landing WM, Lao Y, Lu Y, Measures CI, Moran SB, Morton PL, Ohnemus DC, Robinson LF, Shelley RU.

Philos Trans A Math Phys Eng Sci. 2016 Nov 28;374(2081). pii: 20150285. doi: 10.1098/rsta.2015.0285.

5.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH.

Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.

PMID:
28874350
6.

Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors.

Lin X, Fleisher M, Rosenblum M, Lin O, Boire A, Briggs S, Bensman Y, Hurtado B, Shagabayeva L, DeAngelis LM, Panageas KS, Omuro A, Pentsova EI.

Neuro Oncol. 2017 Sep 1;19(9):1248-1254. doi: 10.1093/neuonc/nox066.

PMID:
28821205
7.

Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer.

Scher HI, Graf RP, Schreiber NA, McLaughlin B, Jendrisak A, Wang Y, Lee J, Greene S, Krupa R, Lu D, Bamford P, Louw JE, Dugan L, Vargas HA, Fleisher M, Landers M, Heller G, Dittamore R.

Cancer Res. 2017 Oct 15;77(20):5687-5698. doi: 10.1158/0008-5472.CAN-17-1353. Epub 2017 Aug 17.

PMID:
28819021
8.

Pseudohypocalcemia in Cancer Patients: A Recommendation for the Postanalytical Correction of Serum Calcium in Patients with Hypoalbuminemia.

Carroll B, Fleisher M, Pessin MS, Richardson S, Ramanathan LV.

Clin Chem. 2017 Jul;63(7):1302-1304. doi: 10.1373/clinchem.2017.272997. Epub 2017 May 17. No abstract available.

PMID:
28515104
9.

Two cases of spontaneous remission of non-parasitic chyluria.

Mendu DR, Sternlicht H, Ramanathan LV, Pessin MS, Fleisher M, Dalbagni G, Jaimes EA, Kaltsas A, Glezerman IG.

Clin Biochem. 2017 Oct;50(15):886-888. doi: 10.1016/j.clinbiochem.2017.05.002. Epub 2017 May 4.

PMID:
28478046
10.

Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.

Scher HI, Graf RP, Schreiber NA, McLaughlin B, Lu D, Louw J, Danila DC, Dugan L, Johnson A, Heller G, Fleisher M, Dittamore R.

Eur Urol. 2017 Jun;71(6):874-882. doi: 10.1016/j.eururo.2016.11.024. Epub 2016 Dec 12.

12.

A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.

Pietanza MC, Litvak AM, Varghese AM, Krug LM, Fleisher M, Teitcher JB, Holodny AI, Sima CS, Woo KM, Ng KK, Won HH, Berger MF, Kris MG, Rudin CM.

Lung Cancer. 2016 Sep;99:23-30. doi: 10.1016/j.lungcan.2016.04.014. Epub 2016 Apr 26.

13.

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Pandit-Taskar N, O'Donoghue JA, Ruan S, Lyashchenko SK, Carrasquillo JA, Heller G, Martinez DF, Cheal SM, Lewis JS, Fleisher M, Keppler JS, Reiter RE, Wu AM, Weber WA, Scher HI, Larson SM, Morris MJ.

J Nucl Med. 2016 Dec;57(12):1858-1864. Epub 2016 Aug 11.

14.

Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.

Lorente D, Olmos D, Mateo J, Bianchini D, Seed G, Fleisher M, Danila DC, Flohr P, Crespo M, Figueiredo I, Miranda S, Baeten K, Molina A, Kheoh T, McCormack R, Terstappen LW, Scher HI, de Bono JS.

Eur Urol. 2016 Dec;70(6):985-992. doi: 10.1016/j.eururo.2016.05.023. Epub 2016 Jun 9.

15.

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, Johnson A, Jendrisak A, Bambury R, Danila D, McLaughlin B, Wahl J, Greene SB, Heller G, Marrinucci D, Fleisher M, Dittamore R.

JAMA Oncol. 2016 Nov 1;2(11):1441-1449. doi: 10.1001/jamaoncol.2016.1828. Erratum in: JAMA Oncol. 2016 Nov 1;2(11):1511.

16.

Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).

Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR Jr, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH.

Cancer. 2016 Aug 1;122(15):2371-8. doi: 10.1002/cncr.30062. Epub 2016 May 10.

17.

Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid.

Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C, Panageas KS, Meng F, Selcuklu SD, Ogilvie S, Distefano N, Shagabayeva L, Rosenblum M, DeAngelis LM, Viale A, Mellinghoff IK, Berger MF.

J Clin Oncol. 2016 Jul 10;34(20):2404-15. doi: 10.1200/JCO.2016.66.6487. Epub 2016 May 9.

18.

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.

Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.

Oncologist. 2016 Apr;21(4):418-24. doi: 10.1634/theoncologist.2015-0321. Epub 2016 Mar 16.

19.

Generation of a novel, multi-stage, progressive, and transplantable model of plasma cell neoplasms.

Asai T, Hatlen MA, Lossos C, Ndiaye-Lobry D, Deblasio A, Murata K, Fleisher M, Cortizas EM, Verdun RE, Petrini J, Nimer SD.

Sci Rep. 2016 Mar 10;6:22760. doi: 10.1038/srep22760.

20.

No iron fertilization in the equatorial Pacific Ocean during the last ice age.

Costa KM, McManus JF, Anderson RF, Ren H, Sigman DM, Winckler G, Fleisher MQ, Marcantonio F, Ravelo AC.

Nature. 2016 Jan 28;529(7587):519-22. doi: 10.1038/nature16453.

PMID:
26819045
21.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.

Li BT, Lou E, Hsu M, Yu HA, Naidoo J, Zauderer MG, Sima C, Johnson ML, Daras M, DeAngelis LM, Fleisher M, Kris MG, Azzoli CG.

PLoS One. 2016 Jan 5;11(1):e0146063. doi: 10.1371/journal.pone.0146063. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0152450.

22.

Development of an Assay for Methotrexate and Its Metabolites 7-Hydroxy Methotrexate and DAMPA in Serum by LC-MS/MS.

Schofield RC, Ramanathan LV, Murata K, Fleisher M, Pessin MS, Carlow DC.

Methods Mol Biol. 2016;1383:213-22. doi: 10.1007/978-1-4939-3252-8_23.

PMID:
26660190
23.

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Sundaresan TK, Sequist LV, Heymach JV, Riely GJ, Jänne PA, Koch WH, Sullivan JP, Fox DB, Maher R, Muzikansky A, Webb A, Tran HT, Giri U, Fleisher M, Yu HA, Wei W, Johnson BE, Barber TA, Walsh JR, Engelman JA, Stott SL, Kapur R, Maheswaran S, Toner M, Haber DA.

Clin Cancer Res. 2016 Mar 1;22(5):1103-10. doi: 10.1158/1078-0432.CCR-15-1031. Epub 2015 Oct 7.

24.

Development and validation of a turbulent flow chromatography and tandem mass spectrometry method for the quantitation of methotrexate and its metabolites 7-hydroxy methotrexate and DAMPA in serum.

Schofield RC, Ramanathan LV, Murata K, Grace M, Fleisher M, Pessin MS, Carlow DC.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Oct 1;1002:169-75. doi: 10.1016/j.jchromb.2015.08.025. Epub 2015 Aug 22.

25.

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.

Scher HI, Heller G, Molina A, Attard G, Danila DC, Jia X, Peng W, Sandhu SK, Olmos D, Riisnaes R, McCormack R, Burzykowski T, Kheoh T, Fleisher M, Buyse M, de Bono JS.

J Clin Oncol. 2015 Apr 20;33(12):1348-55. doi: 10.1200/JCO.2014.55.3487. Epub 2015 Mar 23.

26.

Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis.

Wesa KM, Segal NH, Cronin AM, Sjoberg DD, Jacobs GN, Coleton MI, Fleisher M, Dnistrian AM, Saltz LB, Cassileth BR.

Nutr Cancer. 2015;67(3):424-30. doi: 10.1080/01635581.2015.998838. Epub 2015 Feb 3.

27.

Beneficial effects of perioperative statins for major pulmonary resection.

Amar D, Park B, Zhang H, Shi W, Fleisher M, Thaler HT, Rusch VW.

J Thorac Cardiovasc Surg. 2015 Jun;149(6):1532-8. doi: 10.1016/j.jtcvs.2014.12.016. Epub 2014 Dec 18.

28.

D-lactic acidosis mediated neuronal encephalopathy in acute lymphoblastic leukemia patient: an under diagnosis.

Mendu DR, Fleisher M, McCash SI, Pessin MS, Ramanathan LV.

Clin Chim Acta. 2015 Feb 20;441:90-1. doi: 10.1016/j.cca.2014.12.025. Epub 2014 Dec 24.

PMID:
25542530
29.

Serum biomarkers for assessing histology and outcomes in patients with metastatic lung cancer.

Lou E, Johnson M, Sima C, Gonzalez-Espinoza R, Fleisher M, Kris MG, Azzoli CG.

Cancer Biomark. 2014;14(4):207-14. doi: 10.3233/CBM-140399.

PMID:
24934363
30.

Biological response to millennial variability of dust and nutrient supply in the Subantarctic South Atlantic Ocean.

Anderson RF, Barker S, Fleisher M, Gersonde R, Goldstein SL, Kuhn G, Mortyn PG, Pahnke K, Sachs JP.

Philos Trans A Math Phys Eng Sci. 2014 Jul 13;372(2019):20130054. doi: 10.1098/rsta.2013.0054.

31.

A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.

Shah S, Schrader KA, Waanders E, Timms AE, Vijai J, Miething C, Wechsler J, Yang J, Hayes J, Klein RJ, Zhang J, Wei L, Wu G, Rusch M, Nagahawatte P, Ma J, Chen SC, Song G, Cheng J, Meyers P, Bhojwani D, Jhanwar S, Maslak P, Fleisher M, Littman J, Offit L, Rau-Murthy R, Fleischut MH, Corines M, Murali R, Gao X, Manschreck C, Kitzing T, Murty VV, Raimondi S, Kuiper RP, Simons A, Schiffman JD, Onel K, Plon SE, Wheeler D, Ritter D, Ziegler DS, Tucker K, Sutton R, Chenevix-Trench G, Li J, Huntsman DG, Hansford S, Senz J, Walsh T, Lee M, Hahn CN, Roberts K, King MC, Lo SM, Levine RL, Viale A, Socci ND, Nathanson KL, Scott HS, Daly M, Lipkin SM, Lowe SW, Downing JR, Altshuler D, Sandlund JT, Horwitz MS, Mullighan CG, Offit K.

Nat Genet. 2013 Oct;45(10):1226-1231. doi: 10.1038/ng.2754. Epub 2013 Sep 8.

32.

Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.

Rathkopf DE, Morris MJ, Fox JJ, Danila DC, Slovin SF, Hager JH, Rix PJ, Chow Maneval E, Chen I, Gönen M, Fleisher M, Larson SM, Sawyers CL, Scher HI.

J Clin Oncol. 2013 Oct 1;31(28):3525-30. doi: 10.1200/JCO.2013.50.1684. Epub 2013 Sep 3.

33.

Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.

Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, Dai C, Khanin R, Fleisher M, Lilja H, Scher HI.

Eur Urol. 2014 Jun;65(6):1191-7. doi: 10.1016/j.eururo.2013.07.006. Epub 2013 Jul 26.

34.

Among giants.

Fleisher MR.

Inflamm Bowel Dis. 2013 Sep;19(10):E82. doi: 10.1097/MIB.0b013e318299c9aa. No abstract available.

PMID:
23846490
35.

Image-guided thermal ablation of tumors increases the plasma level of interleukin-6 and interleukin-10.

Erinjeri JP, Thomas CT, Samoilia A, Fleisher M, Gonen M, Sofocleous CT, Thornton RH, Siegelbaum RH, Covey AM, Brody LA, Alago W Jr, Maybody M, Brown KT, Getrajdman GI, Solomon SB.

J Vasc Interv Radiol. 2013 Aug;24(8):1105-12. doi: 10.1016/j.jvir.2013.02.015. Epub 2013 Apr 10.

36.

Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors.

Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, Liu CM, Deangelis LM, Omuro A.

Neurology. 2013 Apr 23;80(17):1598-605; discussion 1603. doi: 10.1212/WNL.0b013e31828f183f. Epub 2013 Apr 3.

37.

Neutrophil gelatinase-associated lipocalin (NGAL) levels in response to unilateral renal ischaemia in a novel pilot two-kidney porcine model.

Silberstein JL, Sprenkle PC, Su D, Power NE, Tarin TV, Ezell P, Sjoberg DD, Feifer A, Fleisher M, Russo P, Touijer KA.

BJU Int. 2013 Aug;112(4):517-25. doi: 10.1111/bju.12066. Epub 2013 Mar 19.

38.

Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.

Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M, Strauss HW, Fleisher M, Heller G, Farooki A.

Leuk Res. 2013 Jul;37(7):790-4. doi: 10.1016/j.leukres.2013.02.005. Epub 2013 Mar 6.

PMID:
23473999
39.

Urine neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after kidney surgery.

Sprenkle PC, Wren J, Maschino AC, Feifer A, Power N, Ghoneim T, Sternberg I, Fleisher M, Russo P.

J Urol. 2013 Jul;190(1):159-64. doi: 10.1016/j.juro.2013.01.101. Epub 2013 Feb 4.

40.

Fluorescent substituted amidines of benzanthrone: synthesis, spectroscopy and quantum chemical calculations.

Gonta S, Utinans M, Kirilov G, Belyakov S, Ivanova I, Fleisher M, Savenkov V, Kirilova E.

Spectrochim Acta A Mol Biomol Spectrosc. 2013 Jan 15;101:325-34. doi: 10.1016/j.saa.2012.09.104. Epub 2012 Oct 12.

PMID:
23123239
41.

NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy.

Moul JW, Lilja H, Semmes OJ, Lance RS, Vessella RL, Fleisher M, Mazzola C, Sarno MJ, Stevens B, Klem RE, McDermed JE, Triebell MT, Adams TH.

Urology. 2012 Dec;80(6):1319-25. doi: 10.1016/j.urology.2012.06.080. Epub 2012 Oct 26.

42.

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study.

Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, Katz L, Subudhi SK, Anand A, Fleisher M, Kantoff PW, Oh WK.

Lancet Oncol. 2012 Nov;13(11):1105-13. doi: 10.1016/S1470-2045(12)70263-2. Epub 2012 Oct 9.

PMID:
23059047
43.

Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.

Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, Fleisher M, Reid AH, Castro E, Sandhu SK, Barwell L, Oommen NB, Carreira S, Drake CG, Jones R, Cooper CS, Scher HI, de Bono JS.

Lancet Oncol. 2012 Nov;13(11):1114-24. doi: 10.1016/S1470-2045(12)70372-8. Epub 2012 Oct 9.

44.

Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI.

Cancer Res. 2012 Dec 1;72(23):6142-52. doi: 10.1158/0008-5472.CAN-12-1335. Epub 2012 Sep 12.

45.

The microculture-kinetic (MiCK) assay: the role of a drug-induced apoptosis assay in drug development and clinical care.

Bosserman L, Prendergast F, Herbst R, Fleisher M, Salom E, Strickland S, Raptis A, Hallquist A, Perree M, Rajurkar S, Karimi M, Rogers K, Davidson D, Willis C, Penalver M, Homesley H, Burrell M, Garrett A, Rutledge J, Chernick M, Presant CA.

Cancer Res. 2012 Aug 15;72(16):3901-5. Epub 2012 Aug 3. Review.

46.

Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases.

Morris PG, Fazio M, Farooki A, Estilo C, Mallam D, Conlin A, Patil S, Fleisher M, Cremers S, Huryn J, Hudis CA, Fornier MN.

J Oral Maxillofac Surg. 2012 Dec;70(12):2768-75. doi: 10.1016/j.joms.2011.12.028. Epub 2012 Feb 11.

PMID:
22330331
47.

Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma.

Rizk NP, Servais EL, Tang LH, Sima CS, Gerdes H, Fleisher M, Rusch VW, Adusumilli PS.

Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):482-6. doi: 10.1158/1055-9965.EPI-11-0993. Epub 2012 Jan 11.

48.

Circulating tumors cells as biomarkers: progress toward biomarker qualification.

Danila DC, Pantel K, Fleisher M, Scher HI.

Cancer J. 2011 Nov-Dec;17(6):438-50. doi: 10.1097/PPO.0b013e31823e69ac. Review.

49.

An in vivo platform for tumor biomarker assessment.

Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M, Rusch VW, Sadelain M, Adusumilli PS.

PLoS One. 2011;6(10):e26722. doi: 10.1371/journal.pone.0026722. Epub 2011 Oct 26.

50.

Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.

Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.

Neuro Oncol. 2011 Nov;13(11):1244-51. doi: 10.1093/neuonc/nor117. Epub 2011 Aug 10.

Supplemental Content

Loading ...
Support Center